Trial
NCT05482074
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
AstraZeneca
Condition
Recurrent Metastatic Melanoma
Intervention
Olaparib
Why stopped
Principal Investigator left the institute
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-19